US FDA approves Santhera's drug for rare muscular dystrophy
Catalyst Pharmaceuticals announced FDA approval for Santhera Pharmaceuticals' DMD treatment, Agamree, for patients aged two and older. The drug, similar to corticosteroids but with fewer side effects, is set for U.S. launch in Q1 2024. Catalyst plans a financial assistance program to enhance drug accessibility.
Reference News
US FDA approves Santhera's drug for rare muscular dystrophy
Catalyst Pharmaceuticals announced FDA approval for Santhera Pharmaceuticals' DMD treatment, Agamree, for patients aged two and older. The drug, similar to corticosteroids but with fewer side effects, is set for U.S. launch in Q1 2024. Catalyst plans a financial assistance program to enhance drug accessibility.